Abnormal activation of HIF-1A and related metabolic target genes in the M2 subtype not only indicates a response to hypoxia-induced therapy but could also be used as a prognostic biomarker for bladder cancer patients. The gene discussed is HIF1A; the disease is urinary bladder carcinoma.